Both langerhans cells and intestinal DC cross-present melanoma antigens and efficiently activate antigen-specific CTL

European Journal of Immunology

Volumn 37, Issue 9, 2007, Pages 2657-2667

  Cao, Tinghua ^a   Ueno, Hideki ^a   Glaser, Casey ^a   Fay, Joseph W ^a   Palucka, A Karolina ^a   Banchereau, Jacques ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

Cancer vaccine; Cross presentation; Dendritic cell subsets; Melanoma

Indexed keywords

CD34 ANTIGEN; DENDRITIC CELL VACCINE; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELANOMA ANTIGEN; MELANOMA VACCINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LANGERHANS CELL; MELANOMA; MELANOMA CELL; MEMORY T LYMPHOCYTE; METASTASIS POTENTIAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; GENE EXPRESSION PROFILING; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NECROSIS; PATHOLOGY;

ANTIGENS, CD34; ANTIGENS, NEOPLASM; APOPTOSIS; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; GENE EXPRESSION PROFILING; HUMANS; LANGERHANS CELLS; LYMPHOCYTE ACTIVATION; MELANOMA; NECROSIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34548735414     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200636499     Document Type: Article

References (61)

1. Banchereau, J. and Steinman, R. M., Dendritic cells and the control of immunity. Nature 1998. 392: 245-252.
2. Davis, I. D., Jefford, M., Parente, P. and Cebon, J., Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. 2003. 73: 3-29.
3. Banchereau, J. and Palucka, A. K., Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 2005. 5: 296-306.
4. Schuler, G., Schuler-Thurner, B. and Steinman, R. M., The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 2003. 15: 138-147
5. Gilboa, E., The promise of cancer vaccines. Nat. Rev. Cancer 2004. 4: 401-411.
6. Rosenberg, S. A., Yang, J. C. and Restifo, N. P., Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 2004. 10: 909-915.
7. Banchereau, J., Palucka, A. K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S. et al., Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001. 61: 6451-6458.
8. Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T. and Falo, L. D., Jr., Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 1996. 183: 283-287.
9. Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M. and Engleman, E. G., Altered peptide ligand vaccination with F1t3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 2001. 98: 8809-8814.
10. Lau, R., Wang, F., Jeffery, G., Marty, V., Kuniyoshi, J., Bade, E., Ryback, M. E. and Weber, J., Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J. Immunother 2001. 24: 66-78.
11. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D., Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 1998. 4: 328-332.
12. + melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. 2000. 165: 3492-3496.
13. Slingluff, C. L., Jr., Petroni, G. R., Yamshchikov, G. V., Barnd, D. L., Eastham, S., Galavotti, H., Patterson, J. W. et al., Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 2003. 21: 4016-4026.
14. de Vries, I. J., Lesterhuis, W. J., Scharenborg, N. M., Engelen, L. P., Ruiter, D. J., Gerritsen, M. J., Croockewit, S. et al., Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 2003. 9: 3091-5100.
15. Zhang, Y., Renkvist, N., Sun, Z., Schuler-Thurner, B., Glaichenhaus, N., Schuler, G. et al., A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur. J. Immunol. 2005. 35: 1066-1075.
16. + progenitor-derived dendritic cells. J. Exp. Med. 2004. 199: 1503-1511.
17. Fay, J. W., Palucka, A. K., Paczesny, S., Dhodapkar, M., Johnston, D. A., Burkeholder, S., Ueno, H. and Banchereau, J., Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol. Immunother. 2006. 10: 1209-1218.
18. + T lymphocytes. Nature 2003. 421: 852-856.
19. Shedlock, D. J. and Shen, H., Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003. 300: 337-339.
20. Sun, J. C. and Bevan, M. J., Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003. 300: 339-342.
21. Albert, M. L., Sauter, B. and Bhardwaj, N., Dendritic cells acquire antigen from apoptotic cells and induce class I- restricted CTLs. Nature 1998. 392: 86-89.
22. Albert, M. L., Pearce, S. F., Francisco, L. M., Sauter, B., Roy, P., Silverstein, R. L. and Bhardwaj, N., Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 1998. 188: 1359-1368.
23. Chang, A. E., Redman, B. G., Whitfield, J. R., Nickoloff, B. J., Braun, T. M., Lee, P. P., Geiger, J. D. and Mule, J. J., A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 2002. 8: 1021-1032.
24. Maier, T., Tun-Kyi, A., Tassis, A., Jungius, F.P., Burg, G., Dummer, R. and Nestle, F. O., Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 2003. 102: 2338-2344.
25. Salcedo, M., Bercovici, N., Taylor, R., Vereecken, P., Massicard, S., Duriau, D., Vernel-Pauillac, F. et al., Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol. Immunother. 2005: 1-11.
26. Timmerman, J. M., Czerwinski, D. K., Davis, T. A., Hsu, F. J., Benike, C., Hao, Z. M., Taidi, B. et al., Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 2002. 99: 1517-1526.
27. Nair, S. K., Morse, M., Boezkowski, D., Cumming, R. L, Vasovic, L., Gilboa, E. and Lyerly, H. K., Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 2002. 235: 540-549.
28. Bonehill, A., Heirman, C., Tuyaerts, S., Michiels, A., Breckpot, K, Brasseur, F., Zhang, Y. et al., Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol. 2004. 172: 6649-6657.
29. Grunebach, F., Muller, M. R. and Brossa, P., New developments in dendritic cell-based vaccinations: RNA translated into clinics. Cancer Immunol. Immunother. 2005. 54: 517-525.
30. + T cell responses in patients with metastatic prostate cancer. J. Immunol. 2005. 174: 3798-3807.
31. Berard, F., Blanco, P., Davoust, J., Neidhart-Berard, E. M., Nouri-Shirazt M., Taquet, N., Rimoldi, D. et al., Cross-priming of Naive CD8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells. J. Exp. Med. 2000. 192: 1535-1544.
32. Nouri-Shirazi, M., Banchereau, J., Bell, D., Burkeholder, S., Kraus, E. T., Davoust, J. and Palucka, K. A., Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J. Immunol. 2000. 165: 3797-3803.
33. Shaif-Muthana, M., McIntyre, C., Sisley, K., Rennie, I. and Murray, A., Dead or alive: Immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res. 2000. 60: 6441-6447.
34. O'Rourke, M. G., Johnson, M., Lanagan, C., See, J., Yang, J., Ben, J. R., Slater, G. J. et al. W., Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. 2003. 52: 387-395.
35. + T-cell immunity. J. Immunother. 2006. 29: 545-557.
36. Shortman, K. and Liu, Y. J., Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2002. 2: 151-161.
37. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J. Exp. Med. 1996. 184: 695-706.
38. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 1997 90: 1458-1470.
39. Nagata, Y., Ono, S., Matsuo, M., Gnjatic, S., Valmori, D., Ritter, G., Garrett, W. et al., Differential presentation of a soluble exogenous tumor antigen, NY-ESO-I, by distinct human dendritic cell populations. Proc. Natl. Acad. Sci. USA 2002. 99: 10629-10634.
40. + hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence ofbioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J. Immunol. 2004. 173: 2780-2791.
41. Muriz, C., Dao, T., Ferlazzo, G., de Cos, M. A., Goodman, YL and Young, J. W., Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating hunian natural killer cells. Blood 2005. 105: 266-273.
42. den Haan, J. M., Lehar, S. M. and Bevan, M. J., CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 2000. 192: 1685-1696.
43. + dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 2002. 195: 1289-1302.
44. Chomez, P., De Backer, O., Bertrand, M., De Plaen, E., Boon, T. and Lucas, S., An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001. 61: 5544-5551.
45. Rubartelli, A., Poggi, A. and Zocchi, M. R., The selective engulftnent of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium. Eur. J. Immunol. 1997. 27: 1893-1900.
46. Nouri-Shirazi, M., Banchereau, J., Fay, J. and Palucka, K., Dendritic cell based tumor vaccines [In Process Citation]. Immunol. Lett. 2000. 74: 5-10.
47. Dalgaard, J., Beckstrom, IC J., Jahnsen, F. L. and Brinchmann, J. E., Differential capability for phagocytosis of apoptotic and necrotic leukemia cells by human peripheral blood dendritic cell subsets. J. Leukoc. Biol. 2005. 77: 689-698.
48. Reis e Sousa, C., Stahl, P. D. and Austyn, J. M., Phagocytosis of antigens by Langerhans cells in vitro. J. Exp. Med. 1993. 178: 509-519.
49. Filgueira, L., Nestle, F. O., Rittig, M., Joller, H. I. and Groscurth, P., Human dendritic cells phagocytose and process Borrelia burgdorferi. J. Immunol. 1996. 157: 2998-3005.
50. + murine dendritic cells. J. Immunol. 2002. 168: 6057-6065.
51. Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J. L., Castedo, M. et al., Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007. 13: 54-61.
52. + dendritic cells but not by Langerhans cells. Science 2003. 301: 1925-1928.
53. Bosnjak, L., Miranda-Saksena, M., Koelle, D. M., Boadle, R. A., Jones, C. A. and Cunningham, A. L., Herpes simplex virus infection of human dendritic cells induces apoptosis and allows cross-presentation via uninfected dendritic cells. J. Immununol. 2005. 174: 2220-2227.
54. Matsuo, M., Nagata, Y., Sato, E., Atanackovic, D., Valmori, D., Chen, Y. T., Ritter, G. et al., IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc. Natl. Acad. Sci. USA 2004. 101: 14467-14472.
55. + progenitors. J. Immunol. 2000. 164: 3600-36O7.
56. Geissmann, F., Revy, P., Regnault, A., Lepelletier, Y., Dy, M., Brousse, N., Amigorena, S., Hermine, O. and Durandy, A., TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 1999. 162: 4567-4575.
57. Valladeau, J. and Saeland, S., Cutaneous dendritic cells. Semin. Immunol. 2005. 17: 273-283.
58. Geissmann, F., Frost, C., Monnet, J. P., Dy, M., Brousse, N. and Hermine, O., Transforming growth factor betal, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J. Exp. Med. 1998. 187: 961-966.
59. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S. et al., Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 1999. 5: 677-685.
60. + hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses. J. Immunol. Methods 2004. 285: 171-180.
61. Shi, H., Can, T., Connolly, J. E., Monnet, L., Bennett, L., Chapel, S., Bagnis, C. et al., Hyperthermia enhances CTL cross-priming. J. Immunol. 2006. 176: 2134-2141.